Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations

ReutersMay 12, 2026 9:14 PM

View all comments（0）



Overview

Canada plant-based ingredient maker's Q1 revenue rose yr/yr on higher sales volumes
Q1 net income turned positive, driven by income from discontinued German operations
Operating expenses for Q1 halved from prior year due to cost reductions

Outlook

Company did not provide specific financial guidance for the current or future periods

Result Drivers

DISCONTINUED OPERATIONS - Net income was primarily driven by $10.9 mln income from discontinued German subsidiaries after their deconsolidation
COST REDUCTIONS - Operating expenses fell due to lower selling, general and administrative costs and reduced R&D spending
HIGHER SALES VOLUMES - Revenue increased yr/yr due to higher sales volumes

Company press release: ID:nGNX6XYjwC

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		$10.80 mln
Q1 Operating Expenses		$1.50 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Nvidia Surges Over 3% in Overnight Trading, Reports Say US Approved Sale of NVDA H200 Chips to 10 Chinese Companies

TradingKey - During the US overnight trading session on May 14 ET, Nvidia (NVDA.US) shares surged, with gains briefly exceeding 3% and hitting a session high of $232.35.

Trump’s China Visit Boosts China Stocks Nearly 4%, Alibaba Favored by AI Bets Despite Weak Results

TradingKey - On May 13 (ET), U.S. President Trump arrived in Beijing to begin a three-day visit. Markets expect both sides to engage in dialogue on issues such as trade and technology, a move that has eased concerns over a further escalation of U.S.-China tensions.

Pricing Hiked Three Times to $185. What Gives Cerebras Confidence in Its $49B Valuation After Spurning SoftBank?

TradingKey - AI chipmaker Cerebras Systems is racing toward a US IPO with momentum far exceeding expectations, as Wall Street's fervor for the AI semiconductor sector is fully reflected in the company.

AI Frenzy vs. Crypto Winter: Cerebras Sets Year’s Largest IPO as Crypto Funding Hits Freezing Point

Market capital is exhibiting a powerful "siphon effect," as funds flow continuously toward AI hardware and infrastructure with clearer technological pathways and more defined revenue models. Conversely, the cryptocurrency sector has fallen out of favor due to the absence of these attributes. This suggests that if crypto enterprises can integrate AI development—such as the AI agent economy—they may have an opportunity to break through the current IPO freeze.

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

TradingKey - Cerebras Systems (CBRS) IPO prices May 13–14 at $125–$135/share. $26–$27B valuation, 20x oversubscribed, $510M revenue, 47% net margin, OpenAI 750MW deal. Everything you need to know.

Featured Tools